Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented Technology Increasing Effectiveness and Potentially Lowering Healthcare Costs
- Company’s patented DehydraTECH(TM) technology is showing the potential of reducing healthcare costs by improving oral medication administration – using capsule and pill form over injection administration
- Lexaria’s offering could potentially offer accelerated regulatory filing with the FDA and other regulators around the world
- The company sub-licenses its DehydraTECH technology for the delivery of fat-soluble active molecules and drugs while also operating four subsidiary companies
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, recently announced results from an anti-viral drug molecular characterization study performed by the National Research Council (“NRC”). Results confirmed that the drugs tested remained stable and did not undergo changes in chemical structure when processed with Lexaria’s patented DehydraTECH(TM) technology. The use of DehydraTECH could preserve the ability of this form of drug delivery to qualify for an accelerated regulatory filing with the United States Food and Drug Administration (“FDA”), plus other regulators around the world.
DehydraTECH provides a potential for cost savings to the health care system by delivering anti-viral drugs more effectively through oral administration. Medication delivery through pill form instead of a shot could potentially help governments or health insurance companies save billions of dollars in administration costs.
Chris Bunka, CEO of DehydraTECH, says that DehydraTECH’s speed and efficacy in delivering a bigger fraction of the drug into the patient’s bloodstream are a result of the technology allowing the drug to bypass the liver and instead enter blood circulation via the lymphatic system.
“One of the reasons people hate taking any drugs is side effects. It might cause diarrhea, headaches, sleepiness, but because (with DehydraTECH) we can use a smaller quantity of drug to achieve the same result, side effects go down,” Bunka further explained (https://nnw.fm/WkvQ4).
Lexaria is currently focused on the applications of DehydraTECH for the administration of hypertension medication but the technology has multiple applications to improve absorption rates for substances ranging from nicotine and cannabinoids to anti-viral medication, including COVID-19 applications. After finalizing current clinical studies on hypertension, the company plans to work with antivirals to help people who need them, especially where vaccination availability is low.
The company also sub-licenses the DehydraTECH technology for the delivery of fat-soluble active molecules and drugs. There are currently four subsidiary companies that Lexaria is focusing on, which include different commercial opportunities in their respective industries. These subsidiaries include Lexaria Pharma Corp., Lexaria Nicotine Corp., Lexaria Hemp Corp., and Lexaria Canpharm Corp.
Lexaria Pharma Corp. – investigates new products for hypertension, antivirals, and other drug classes
Lexaria Nicotine Corp. – 16.67% owned by Altria Ventures Inc. and investigates the oral, non-combusted tobacco-derived nicotine product format opportunities
Lexaria Hemp Corp. – pursuing business-to-business opportunities with cannabinoids, including cannabidiol (“CBD”) from hemp
Lexaria Canpharm Corp. – state-of-the-art Health Canada-licensed lab capable of developing novel psychotropic cannabinoid formulations for potential commercialization in federally legal sectors
Hill Street Beverage Company Inc. (TSX.V: BEER) is one of the companies that sub-licenses the DehydraTECH technology from Lexaria. With the company’s alcohol-free wine popularity, Hill Street Beverage is fueling other strategic priorities, including Hill Avenue Cannabis, using Lexaria’s DehydraTECH technology (https://nnw.fm/oj62U). Craig Brinkley, Co-CEO of Hill Street, stated that “The acquisition of the global usage rights for patented DehydraTECH from the Lexaria group of companies, aimed at growing our cannabis business worldwide, has also mobilized the company to expand our geographic footprint across all of our business lines including the new global export strategy for alcohol-free beverages.”
For more information, visit the company’s website at www.LexariaBioscience.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Company’s patented DehydraTECH(TM) technology is showing the potential of reducing healthcare costs by improving oral medication administration – using capsule and pill form over injection administration
- Lexaria’s offering could potentially offer accelerated regulatory filing with the FDA and other regulators around the world
- The company sub-licenses its DehydraTECH technology for the delivery of fat-soluble active molecules and drugs while also operating four subsidiary companies
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, recently announced results from an anti-viral drug molecular characterization study performed by the National Research Council (“NRC”). Results confirmed that the drugs tested remained stable and did not undergo changes in chemical structure when processed with Lexaria’s patented DehydraTECH(TM) technology. The use of DehydraTECH could preserve the ability of this form of drug delivery to qualify for an accelerated regulatory filing with the United States Food and Drug Administration (“FDA”), plus other regulators around the world.
DehydraTECH provides a potential for cost savings to the health care system by delivering anti-viral drugs more effectively through oral administration. Medication delivery through pill form instead of a shot could potentially help governments or health insurance companies save billions of dollars in administration costs.
Chris Bunka, CEO of DehydraTECH, says that DehydraTECH’s speed and efficacy in delivering a bigger fraction of the drug into the patient’s bloodstream are a result of the technology allowing the drug to bypass the liver and instead enter blood circulation via the lymphatic system.
“One of the reasons people hate taking any drugs is side effects. It might cause diarrhea, headaches, sleepiness, but because (with DehydraTECH) we can use a smaller quantity of drug to achieve the same result, side effects go down,” Bunka further explained (https://nnw.fm/WkvQ4).
Lexaria is currently focused on the applications of DehydraTECH for the administration of hypertension medication but the technology has multiple applications to improve absorption rates for substances ranging from nicotine and cannabinoids to anti-viral medication, including COVID-19 applications. After finalizing current clinical studies on hypertension, the company plans to work with antivirals to help people who need them, especially where vaccination availability is low.
The company also sub-licenses the DehydraTECH technology for the delivery of fat-soluble active molecules and drugs. There are currently four subsidiary companies that Lexaria is focusing on, which include different commercial opportunities in their respective industries. These subsidiaries include Lexaria Pharma Corp., Lexaria Nicotine Corp., Lexaria Hemp Corp., and Lexaria Canpharm Corp.
Lexaria Pharma Corp. – investigates new products for hypertension, antivirals, and other drug classes
Lexaria Nicotine Corp. – 16.67% owned by Altria Ventures Inc. and investigates the oral, non-combusted tobacco-derived nicotine product format opportunities
Lexaria Hemp Corp. – pursuing business-to-business opportunities with cannabinoids, including cannabidiol (“CBD”) from hemp
Lexaria Canpharm Corp. – state-of-the-art Health Canada-licensed lab capable of developing novel psychotropic cannabinoid formulations for potential commercialization in federally legal sectors
Hill Street Beverage Company Inc. (TSX.V: BEER) is one of the companies that sub-licenses the DehydraTECH technology from Lexaria. With the company’s alcohol-free wine popularity, Hill Street Beverage is fueling other strategic priorities, including Hill Avenue Cannabis, using Lexaria’s DehydraTECH technology (https://nnw.fm/oj62U). Craig Brinkley, Co-CEO of Hill Street, stated that “The acquisition of the global usage rights for patented DehydraTECH from the Lexaria group of companies, aimed at growing our cannabis business worldwide, has also mobilized the company to expand our geographic footprint across all of our business lines including the new global export strategy for alcohol-free beverages.”
For more information, visit the company’s website at www.LexariaBioscience.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
